EAU26 non-promotional Bladder Cancer Industry Seminar
EAU26 non-promotional Bladder Cancer Industry Seminar
Featuring expert insights from Prof. Jonathan Aning, Prof. Alexandra Masson-Lecomte, and Dr. Francesco Soria on current unmet needs in patients with HR-NMIBC experiencing BCG failure.
Watch our industry seminar via the links shown below.
Challenges in high-risk NMIBC: addressing current unmet meeds to optimise patient care
The expert panel discusses unmet needs and tailored management strategies for patients with HR-NMIBC experiencing disease recurrence after BCG, by presenting three patient cases.
After this seminar, the participants should be able to:
- Identify the current unmet needs in the HR-NMIBC setting
- Discuss the complexities of risk stratification and classification of patients with HR-NMIBC
Session Agenda
14:15–14:20 | Welcome and introductions | Jonathan Aning |
14:20–14:35 | Meet my patients: assessing patient risk in NMIBC | Francesco Soria |
14:35–14:50 | Disease recurrence after BCG: what comes next today? | Alexandra Masson-Lecomte |
14:50–15:10 | Strategies for risk stratification and assessment of response All faculty,to BCG: today’s challenges and how to overcome them | All faculty, moderated by Jonathan Aning |
15:10–15:15 | Final remarks and closing | Jonathan Aning |
The recorded content may not be available in your country. To request access to recordings and session materials, please contact our team.
Hear from the Experts
Prof. Jonathan Aning
Prof. Aning discusses real-world challenges and practical strategies in managing patients with HR-NMIBC after BCG failure, emphasising the importance of multidisciplinary team collaboration and involving patients in decision-making.
Dr. Francesco Soria
Dr. Soria addresses the challenges in risk-stratification and progression assessment in NMIBC, shares his insights into guideline recommendations and on-line tools, and provides practical tips on imaging, TURBT, and BCG induction and maintenance.
Past Events
If you registered for a previous session but were unable to attend, you can log in to access recorded sessions and request materials. Please note that for some recordings and materials, the content may not be available in your country.
ECP 2025
An expert panel - Prof. Glen Kristiansen, Dr. Alessia Cimadamore, Dr. Dora Niedersüβ-Beke, and Dr. Beatriz Bellosillo – discuss progress in early genetic testing, personalised care, and multidisciplinary approaches in uropathology.
ESMO 2025
An expert panel – including Prof. Enrique Grande, Prof. Syed Hussain, and Dr. Patrizia Giannatempo – examine key clinical considerations in GU cancer care.
EMUC 2025
A panel of expert speakers at our bladder cancer industry symposium explore the latest treatment strategies in BCG-unresponsive HR-NMIBC.
ⓘ The recorded content may not be available in your country. To request access to recordings and session materials, please contact our team. |
Related Content
Introducing J&J withMe
A patient-centric platform designed to support patients throughout their healthcare journey. It provides personalised, high-quality content and services to enhance patient engagement.
By empowering informed, proactive patients, J&J withMe helps improve treatment outcomes.
Learn how this platform can strengthen your patient relationships: explore J&J withMe today!
Register with J&J Medical Cloud to access our full education library, including recordings, slides, and new session announcements.
Stay in Touch
Contact us
To report an Adverse Event (medication side-effect) or a Product Quality Complaint (an issue with one of our products), please select the appropriate link from the Contact dropdown menu. To submit a medical information request, choose the Medical Information page.
Abbreviations
BCG, Bacillus Calmette–Guérin; EAU, European Association of Urology; HR-NMIBC, high-risk non-muscle invasive bladder cancer; TURBT, transurethral resection of bladder tumour.
CP-572116 - May 2026
Janssen Pharmaceutica NV
